DF
CRNX icon

Dunhill Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Dunhill Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61 Sell
1
-1
-50% -$45 ﹤0.01% 1555
2025
Q4 		$79 Buy
+2
New +$89 ﹤0.01% 1476

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Dunhill Financial's CRNX Position: Q1 2026 in Review

Dunhill Financial reduced its Crinetics Pharmaceuticals (CRNX) stake by 50% in Q1 2026, selling an estimated $45 and leaving 1 share worth $61. The position accounts for ﹤0.01% of the portfolio, ranked #1555.

Dunhill Financial first reported a position in CRNX in Q4 2025 and has held it in 2 quarters since. The position peaked at $79 in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Dunhill Financial held 1 share of Crinetics Pharmaceuticals worth $61 as of Q1 2026.
  • Dunhill Financial sold 1 Crinetics Pharmaceuticals share in Q1 2026, an estimated $45.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Dunhill Financial's portfolio in Q1 2026, its #1555 holding.
  • Dunhill Financial first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Dunhill Financial's Crinetics Pharmaceuticals position peaked at $79 in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.